FARON PHARMACEUTICALS OY
Clinical-stage biopharmaceutical company developing immunotherapies for cancer.
FARN | IL
Overview
Corporate Details
- ISIN(s):
- FI4000153309
- LEI:
- 7437009H31TO1DC0EB42
- Country:
- Finland
- Address:
- Joukahaisenkatu 6, FI-20520 TURKU
- Website:
- https://faron.com/
- Sector:
- Manufacturing
Description
Faron Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for cancer. The company pioneers macrophage-targeting therapies to leverage the patient's immune system, aiming to address unmet medical needs and improve outcomes. Its lead asset, bexmarilimab, is a first-in-class anti-Clever-1 antibody and a myeloid cell-targeting immunotherapy candidate. Bexmarilimab is being investigated in clinical trials as a potential therapy for hematological malignancies and solid tumors, often in combination with standard-of-care treatments.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-02-28 17:00 |
Replacement - Update to 2024 Financial Calendar
|
English | 14.9 KB | ||
| 2024-02-27 19:00 |
Update to Faron’s Financial Calendar for 2024
|
English | 12.0 KB | ||
| 2024-02-21 15:00 |
Continued Negotiations Regarding Events of Default
|
English | 17.7 KB | ||
| 2024-02-19 11:30 |
Events of Default
|
English | 16.3 KB | ||
| 2024-01-31 08:00 |
Further re: Exercise of options
|
English | 15.6 KB | ||
| 2024-01-25 08:00 |
BEXMAB Insights into Patient Profiles
|
English | 17.9 KB | ||
| 2024-01-19 14:00 |
Exercise of options - Issue of equity
|
English | 17.3 KB | ||
| 2024-01-09 08:00 |
First Patient Dosed in Ph 2 of the BEXMAB Trial
|
English | 18.4 KB | ||
| 2024-01-03 08:00 |
Presentation at J.P. Morgan Healthcare Conference
|
English | 9.2 KB | ||
| 2023-12-22 08:00 |
Faron’s Financial Calendar for 2024
|
English | 10.8 KB | ||
| 2023-12-11 08:00 |
Phase 1 BEXMAB data presented at ASH
|
English | 23.5 KB | ||
| 2023-12-07 08:00 |
MATINS Trial in Cell Reports Medicine
|
English | 19.5 KB | ||
| 2023-12-04 08:00 |
Grant of options
|
English | 35.6 KB | ||
| 2023-11-06 09:13 |
Faron Initiates Phase 2 Part of BEXMAB Study
|
English | 21.8 KB | ||
| 2023-11-06 08:00 |
Faron Initiates Phase 2 Part of BEXMAB Study
|
English | 16.3 KB |
Automate Your Workflow. Get a real-time feed of all FARON PHARMACEUTICALS OY filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for FARON PHARMACEUTICALS OY
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for FARON PHARMACEUTICALS OY via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
